# The U-shaped association between normal-range serum bile acid levels and prognosis of Coronary Heart Disease

**Authors:** Yu Xu, Ning Ding, Rui Hua, Yue Wu, Ting Li, Zuyi Yuan

PMC · DOI: 10.3389/fendo.2025.1730403 · 2026-01-12

## TL;DR

This study finds that both high and low bile acid levels in patients with heart disease are linked to worse outcomes, with a U-shaped risk pattern.

## Contribution

The study reveals a U-shaped relationship between normal-range bile acid levels and cardiovascular risk in Coronary Heart Disease patients.

## Key findings

- Patients with mid-range bile acid levels had the lowest risk of major adverse cardiovascular events.
- Both high and low bile acid levels were associated with increased risk of adverse events.
- Adding bile acid levels to risk models improved prediction accuracy for heart disease outcomes.

## Abstract

Previous studies have shown that serum total bile acid levels are associated with both the presence of Coronary Heart Disease and the severity of coronary artery lesions. Coronary Heart Disease progression frequently involves an imbalance in bile acid metabolism. This study aims to evaluate the predictive value of total bile acid levels for the occurrence of major adverse cardiovascular events in patients with Coronary Heart Disease.

A total of 2,974 patients with Coronary Heart Disease who met the inclusion criteria were categorized into four groups based on the quartiles of their total bile acid levels: Group 1 (0.2-1.9 µmol/L, n = 760), Group 2 (1.9-3.1 µmol/L, n = 758), Group 3 (3.1-5.1 µmol/L, n = 741), and Group 4 (5.1-10 µmol/L, n = 715). Survival differences among the groups were evaluated using Kaplan-Meier curves. Multivariate Cox regression analysis was performed to assessed their associations. Restricted cubic spline models were employed to investigate potential nonlinear relationships. Subgroup interaction and incremental predictive value analyses were additionally performed.

Over a median follow-up period of 75 months, Group 2 exhibited a significantly lower incidence of major adverse cardiovascular events compared to the other groups. Kaplan-Meier survival analyses also demonstrated that participants in Group 2 exhibited significantly higher cumulative survival rates free of major adverse cardiovascular events compared to those in the other groups. Multivariate Cox regression revealed that both higher and lower total bile acid levels were associated with an increased risk of major adverse cardiovascular events (HRQ1 = 1.91, p<0.001; HRQ4 = 1.62, p<0.001). Furthermore, Restricted cubic spline analysis indicated a significant nonlinear, U-shaped relationship between total bile acid levels and major adverse cardiovascular events, which was statistically significant in males but not in females. Moreover, risk model analysis demonstrated that adding TBA to a conventional model significantly improved risk discrimination and reclassification.

Total bile acid levels have predictive value for major adverse cardiovascular events in Coronary Heart Disease patients. This finding substantiates the predictive value of total bile acid as an effective risk stratification tool for patients with Coronary Heart Disease after hospital discharge.

## Linked entities

- **Diseases:** Coronary Heart Disease (MONDO:0005010)

## Full-text entities

- **Genes:** MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, NR1H4 (nuclear receptor subfamily 1 group H member 4) [NCBI Gene 9971] {aka BAR, FXR, HRR-1, HRR1, PFIC5, RIP14}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, SMPD3 (sphingomyelin phosphodiesterase 3) [NCBI Gene 55512] {aka NSMASE2}, NR0B2 (nuclear receptor subfamily 0 group B member 2) [NCBI Gene 8431] {aka SHP, SHP1}, SREBF1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 6720] {aka HMD, IFAP2, SREBP1, bHLHd1}, GPBAR1 (G protein-coupled bile acid receptor 1) [NCBI Gene 151306] {aka BG37, GPCR19, GPR131, M-BAR, TGR5}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** cardiotoxic (MESH:D066126), coronary artery lesions (MESH:D003324), biliary obstructive diseases (MESH:D001157), liver insufficiency (MESH:D048550), Myocardial Infarction (MESH:D009203), TBA (MESH:C567652), coronary artery stenosis (MESH:D023921), dyslipidemia (MESH:D050171), inflammation (MESH:D007249), cardiomyopathy (MESH:D009202), diabetes (MESH:D003920), atherosclerosis (MESH:D050197), Heart Failure (MESH:D006333), death (MESH:D003643), ischemia (MESH:D007511), cardiovascular disease (MESH:D002318), Coronary Heart Disease (MESH:D003327), /R (MESH:C580424), cancer (MESH:D009369), familial hypercholesterolemia (MESH:D006938), heart injury (MESH:D006335), acute coronary syndrome (MESH:D054058), Stroke (MESH:D020521), renal insufficiency (MESH:D051437), thrombosis (MESH:D013927), stenosis (MESH:D003251), hypertension (MESH:D006973)
- **Chemicals:** cholesterol (MESH:D002784), Bile acids (MESH:D001647), alcohol (MESH:D000438), TG (MESH:D014280), reactive oxygen species (MESH:D017382), creatinine (MESH:D003404), TBA (-), ursodeoxycholic acid (MESH:D014580), lipid (MESH:D008055), deoxycholic acid (MESH:D003840), glucose (MESH:D005947)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12797419/full.md

---
Source: https://tomesphere.com/paper/PMC12797419